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and Hugh D. Piggins1
1Faculty of Life Sciences, University of Manchester, Manchester M13 9PT, United Kingdom and 2King’s College London and MRC National Institute for
Medical Research, London NW7 1AA, United Kingdom
Circadian and homeostatic neural circuits organize the temporal architecture of physiology and behavior, but knowledge of their inter-
actions is imperfect. For example, neurons containing the neuropeptide orexin homeostatically control arousal and appetitive states,
while neurons in the suprachiasmatic nuclei (SCN) function as the brain’s master circadian clock. The SCN regulates orexin neurons so
that they aremuchmore active during the circadiannight than the circadianday, but it is unclearwhether the orexinneurons reciprocally
regulate the SCN clock. Here we show both orexinergic innervation and expression of genes encoding orexin receptors (OX1 and OX2) in
themouse SCN, with OX1 being upregulated at dusk. Remarkably, we find through in vitro physiological recordings that orexin predom-
inantly suppresses mouse SCN Period1 (Per1)-EGFP-expressing clock cells. The mechanisms underpinning these suppressions vary
across the circadian cycle, from presynaptic modulation of inhibitory GABAergic signaling during the day to directly activating leak K
currents at night. Orexin also augments the SCN clock-resetting effects of neuropeptide Y (NPY), another neurochemical correlate of
arousal, and potentiates NPY’s inhibition of SCN Per1-EGFP cells. These results build on emerging literature that challenge the widely
held view that orexin signaling is exclusively excitatory and suggest new mechanisms for avoiding conflicts between circadian clock
signals and homeostatic cues in the brain.
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Introduction
Temporal organization of behavioral and metabolic states arises
from the integrated activities of circadian and homeostatic neural
networks. For example, key circuits involved in setting patterns of
sleep and arousal include orexin/hypocretin (orexin A and B)
neurons in the tuberal hypothalamus, and circadian clock neu-
rons of the suprachiasmatic nuclei (SCN). Within the SCN, the
molecular circadian clock (of which the Period1-2 genes are key
components) drives daily rhythms in electrical activity, with rhyth-
mic SCN neurons being maximally active during the circadian day
andminimally active across the circadian night (Ikeda, 2004; Brown
and Piggins, 2007). Such pronounced day–night variation in a neu-
ronal state allows theSCNtocommunicate temporal information to
the rest of the brain and body. In nocturnal rodents, SCN output
signals directly and/or indirectly suppress neural centers controlling
motor activity and arousal during the day (Li et al., 2012). Indeed,
the activity of the orexin neurons whose activation and suppression
plays critical roles in the timing of arousal and sleep states (Chemelli
et al., 1999; Tsunematsu et al., 2011) is under SCN circadian control
(Zhang et al., 2004). In rats and mice, orexin neuronal activity (Es-
tabrooke et al., 2001; Marston et al., 2008) and orexin release are
most prevalent throughout their behaviorally active circadian night
(Deboer et al., 2004).
Intriguingly the phase of the SCN circadian clock is also sen-
sitive to feedback from arousal stimuli, particularly during the
circadian day (Mistlberger and Antle, 2011; Hughes and Piggins,
2012). Such stimuli can recruit neuropeptide Y (NPY)-
containing neurons of the intergeniculate leaflet (IGL), which
project to the SCN via the geniculohypothalamic tract (GHT;
Harrington, 1997). NPY released from the GHT suppresses SCN
neuronal activity (Gribkoff et al., 1998), inhibits clock gene ex-
pression in the SCN (Maywood et al., 2002), and in doing so shifts
the phase and output of the clock.During the day, orexin neurons
are also activated by such arousal-promoting stimuli (Estabrooke
et al., 2001; Marston et al., 2008; Webb et al., 2008). Given that
orexin-synthesizing neurons project widely throughout the brain
(Peyron et al., 1998; Nambu et al., 1999), including structures of
the neural circadian system (Ba¨ckberg et al., 2002), orexin re-
leased during states of arousal may also influence SCN cellular
activity. However, this raises an interesting paradox because ac-
tivation of brain orexin receptors is generally considered excit-
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atory (Kukkonen, 2013) and yet SCN neuronal activity is low
across the circadian night when orexin neuronal excitability and
release in nocturnal rodents are maximal.
Here, we demonstrate that unlike its typical excitatory actions in
thebrain, orexinA (OXA)actswithin the SCNtoprimarily suppress
cellular activity, and that themechanisms underlying neuronal sup-
pression differ across the circadian cycle. In addition, we demon-
strate that OXA application does not itself shift the phase of the
clockwork, but instead orexin can enhance the actions of NPY on
SCN clock cells. These results indicate that the output of the master
circadian pacemaker is modulated by homeostatic circuits involved
in arousal and energy balance in amanner that allows acute adapta-
tion to changes in the internal and external environments.
Materials andMethods
Animals
For calcium imaging, electrophysiological, PCR, and immunohisto-
chemical investigations, this study used male and female mice [(8 weeks
to 6 months old) hemizygous for the Period1::d2EGFP transgene (Per1-
EGFP-expressing mice in which an enhanced destabilized green fluores-
cent protein (EGFP) reports the activity of the Per1 promoter; a gift from
Professor D. McMahon, Vanderbilt University; Kuhlman et al., 2000)].
For luminometric assessment of the actions of orexin on the phase of the
molecular circadian clock, adult (8 weeks to 6 months) male mPeriod2Luc
knockin mice (PER2::LUC, a fusion protein of PERIOD2 and firefly
luciferase (LUC; Yoo et al., 2004) were used. For additional immunohis-
tochemical controls, we also used brain tissue from four mice lacking
complete expression of the orexin gene (prepro-orexin knock-out mice;
Chemelli et al., 1999). These brainswere kindly provided byDrB. Boutrel
(Department of Psychiatry, University of Lausanne, Switzerland). Per1-
EGFP and PER2::LUC mice were bred and supplied by the Biological
Services Facility of the University of Manchester. These animals were
group-housed on a 12 h light/dark cycle (lights on at 07:00), and with
food available ad libitum. Prepro-orexin knock-out animals were bred at
the University of Lausanne and maintained under similar lighting and
feeding conditions as described for mice in Manchester (the absence of
orexin expression is well established in these mice; Chemelli et al., 1999).
All experimental procedures were performed according to the provisions
of the UK Animal (Scientific Procedures) Act 1986.
Preparation of living mouse SCN brain slices
For in vitrowhole-cell recordings.All brain sections were prepared during
the subjective day at zeitgeber (ZT) 1–6 or 10–11 (where ZT12 corre-
sponds to lights-off) to reduce possible phase-shifting effects of the slice
preparation (Gillette et al., 1995). Coronal brain slices containing the
middle level of the rostrocaudal SCN were prepared from 80 male and
female Per1-EGFP mice, as previously described (Belle et al., 2009).
Briefly, animals were deeply anesthetized with isoflurane and killed by
decapitation. The brain was immediately removed and 250-m-thick
coronal slices were cut using a vibroslicer (Campden Instruments) in an
ice-cold (4°C) low Na/Ca2, high Mg2 sucrose-based artificial CSF
(aCSF) containing the following (inmM): 95 NaCl, 1.8 KCl, 1.2 KH2PO4,
0.5 CaCl2, 7 MgSO4, 26 NaHCO3, 15 glucose, 50 sucrose, 0.005 mg/L
Phenol Red, oxygenated with 95%O2, 5% CO2, pH 7.4, andmeasured
osmolarity 300–310 mOsmol/kg. For whole-cell patch-clamp record-
ings, slices were transferred to a recording chamber and continuously
perfused (3 ml/min) with recording aCSF. The composition of the re-
cording aCSF was identical to the incubation solution except for the
following (mM): 127 NaCl, 2.4 CaCl2, 1.3 MgSO4, and 0 sucrose. In
recordings where Low Ca2/high Mg2 were required, the aCSF con-
tained 0.3mMCa2 and 9mMMg2 (Burdakov et al., 2006). Recordings
were performed at 23°C.
For in vitro luminometry recordings. SCN brain slices from PER2::LUC
mice were prepared as described previously (Guilding et al., 2009).
Briefly, mice were culled by cervical dislocation following isoflurane an-
esthesia. Brains were then removed and moistened with ice-cold HBSS
(Sigma) supplementedwith 0.035% sodiumbicarbonate (Sigma), 10mM
HEPES (Sigma), and 100g/ml penicillin-streptomycin (Gibco Invitro-
gen). Coronal brain slices (250 m thick) were cut using a vibroslicer
(Camden Instruments) and transferred to sterile tissue culture dishes
(Corning) in cold HBSS. Using a dissecting microscope, the SCN were
identified and microdissected before excised unilateral SCN nuclei were
cultured on interface-style cell culture inserts (PICM0RG50; Millipore)
in standard 35 mm plastic-based cultures dishes (Corning). One millili-
ter of sterile culture medium [DMEM (D-2902; Sigma) supplemented
with 3.5 g/L D-glucose (Sigma), 0.035% sodium bicarbonate (Sigma), 10
mM HEPES buffer (Sigma), 25 g/ml penicillin-streptomycin (Gibco),
B27 (Invitrogen) and 0.1 mM luciferin (Promega) in autoclaved Milli-Q
water] was used per culture. Dishes were sealed with a glass coverslip
using autoclaved high-vacuum grease (Dow Corning) and transferred
directly to light-tight incubators (Galaxy R; RS Biotech) equipped with
photomultiplier tube assemblies (H8259/R7518P; Hamamatsu) for pho-
ton acquisition (integrated for 299 s every 3 min). The incubators were
maintained at 37°C.
Whole-cell recordings
Targeted recordings (current clamp or voltage clamp) were made from
Per1-EGFP-positive (henceforth referred to as Per1-EGFP) neurons, vi-
sually identified using a Leica epifluorescent microscope (DMLFS; Leica
Microsystems) equipped with a Leica camera and capturing software
(DFC 350 FX and Application Suite; Leica Microsystems), as previously
described (Belle et al., 2009; Scott et al., 2010). Final gigaohm seal and cell
membrane rupture were done under infrared video-enhanced differen-
tial interference contrast microscopy. For current-clamp recordings an
Axoclamp 2A amplifier (Molecular Devices) in bridge mode was used
(Belle et al., 2009). Patch pipette electrodes (7–10 M) were fashioned
from thick-walled borosilicate glass capillaries (Harvard Apparatus) us-
ing a two-stage vertical micropipette puller (PB-7; Narishige). Unless
otherwise stated, electrodes were filled with an internal solution contain-
ing the following (in mM): 130 K-gluconate, 10 KCl, 2 MgCl2, 2 K2-ATP,
0.5 Na-GTP, 10 HEPES, and 0.5 EGTA, pH adjusted to 7.3 with KOH,
measured osmolarity 295–300 mOsmol/kg). In some recordings,
K-gluconate was substituted for equimolar KCl. Input resistance (Rinput)
was estimated by a series of hyperpolarizing current pulses (10 to30
pA for 500ms). Signals were sampled at 30 kHz, and stored and analyzed
on a personal computer using Spike2 software (Cambridge Electronic
Design, CED). All data acquisition and step protocols were generated
through a micro 1401 mkII interface (CED).
Synaptic current measurement. Synaptic current activity was measured
with an Axopatch 200B amplifier (Molecular Devices). To record min-
iature and spontaneous postsynaptic currents (mPSCs and sPSCs, re-
spectively), patch pipettes (4–6M)were filledwith an internal solution
that was identical to the one used in current-clamp recordings, except for
120mMK-gluconate and 20KClmM. In SCNneurons, this concentration
of Cl in the intracellular pipette solution causes the IPSCs to reverse
between 40 to 50 mV (data not shown; but see Itri and Colwell,
2003). This positive shift in Cl reversal potential causes bothGABA and
glutamate PSCs to appear as inward currents when membrane voltage is
clamped at70 mV. To discriminate between excitatory and inhibitory
PSCs, a mixture of receptor antagonists (D-2-amino-5-phosphonopentanoate,
AP-5; 6-cyano-7-nitroquinoxaline-2,3-dione, CNQX; and 2,3-dioxo-6-
nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide, NBQX)
for the glutamate receptors and/or for the GABAA receptor (gabazine)
were used. All recording protocols were similar to established methods
for measuring PSCs in SCN neurons (Itri and Colwell, 2003).
Whole-cell leak K current measurement. Slow voltage ramps from 0 to
120mV, at a rate of 20mV/s, were performed using patch pipettes (3–5
M) filled with an internal solution that was identical to the one used in
previous current-clamp recordings above. These ramps were sufficiently
slow to allow background leak currents to achieve steady-state conduc-
tance at each potential (Liu et al., 2002; Jackson et al., 2004). Pipette and
cell capacitive transients were compensated. Membrane series resistance
was20 M and was compensated (70–80%). Seal resistance was typ-
ically10 G, and access resistance20 M. Recordings in which the
series resistance changed by15%were not included for analysis. Signals
for voltage-clamp recordings were acquired using pClamp 10.2 and an-
alyzed off-line using Clampfit 10.2 (Molecular Devices). All data acqui-
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sition and ramp protocols under voltage-clamp conditions were
generated through aDigidata 1440A interface using the pClamp software
(Molecular Devices).
Calcium imaging
SCN brain slices (200 m thick) were prepared from 2- to 6-month-old
Per1-EGFP mice (n  18), as described above. Multiple SCN neurons
maintained in these hypothalamic slices were loaded with the leakage-
resistant calcium-sensitive dye fura-2 AM (LeakRes fura-2; TEFlabs; 1
mM stock made on the day of the experiment in 20% Pluronic F-127 in
dimethylsulfoxide (DMSO); Molecular Probes/Invitrogen) for record-
ing of intracellular calcium responses simultaneously in all loaded cells
(Fig. 2A). Methods for calcium loading were modified from previous
work on SCN and other hypothalamic neurons (Irwin and Allen, 2007,
2010; Yuste et al., 2011). Here, hypothalamic slices containing the mid-
rostrocaudal section of the SCNwere incubated with LeakRes fura-2 AM
(10 M) in well gassed (95% O2 and 5% CO2) aCSF at 37°C for 20 min,
followed by 1 h incubation at room temperature. During incubation, the
gaseous composition immediately above the aCSF in which the SCN
slices were kept was maintained at 95% O2 and 5% CO2. Following
incubation, slices were washed in gassed aCSF for 1.5 h in a holding
chamber to allow for fura-2 AM de-esterification. The SCN brain slices
were then transferred to a recording chamber and maintained in a con-
tinuous flow of aCSF (1–2 ml/min). The composition of the aCSF used
for calcium imaging was similar to the recording solution used for elec-
trophysiology, except phenol red was omitted to avoid any optical dis-
tortion of the fluorescent images. Ratiometric intracellular calcium
([Ca 2]i ratio) levels were measured from pairs of background-
subtracted intensity images (14 bit, 1.24  1.24 mega pixels) captured
every 2 s at 510 nm by a cooled Rolera EM-C2 camera (QImaging) from
excitation wavelengths at 365 nm (isosbestic point for fura-2) and 385
nm. Here, a rise or drop in ([Ca2]i levels caused an increase or decrease
in F365/F385 wavelengths, respectively. The sensitivity of this camera
system allowsminimal light exposure of SCN neurons at these excitation
wavelengths, which significantly prolongs recording time with minimal
photo-bleaching. All calcium imaging was done on an upright Olympus
microscope using a water-immersion UV objective (UMPlanFL N 20/
0.5 Olympus). Florescence was excited by 365 and 385 nm Opto-Light-
Emitting Diodes (OptoLED; Cairn Research; Briston et al., 2011),
controlled by the acquisition software OptoFluor (Cairn Research and
Molecular Devices). Image capture and analysis were done in OptoFluor
(Cairn Research). Acquisition time, camera setup, and LED intensities
were adjusted to minimize photo-bleaching while maintaining excellent
signal-to-noise ratio. Intracellular calcium response (increase, decrease,
or no effect) to OXA in the presence/absence of various antagonists was
defined by a ratio change2 SDs from themean of 10 baseline calcium
ratios recorded before OXA application (Irwin and Allen, 2010). The
magnitude of calcium response was determined as themaximal response
after 3 min of OXA application.
Drugs and analysis
Stock solutions for an orexin receptor 1 (OX1) antagonist (SB 334867),
quinidine, and GABAB receptor antagonist (CGP55845) were prepared
by dissolving in DMSO: final concentration of DMSO in extracellular
solutions did not exceed 0.001%. OXA, tetrodotoxin (TTX), AP-5,
CNQX,NBQX, quinine, and gabazine (Tocris Bioscience)were dissolved
in aCSF and NPY (Tocris Bioscience) in purified water. 1,2-Bis(2-
aminophenoxy) ethane-N,N,N	,N	-tetraacetic acid (BAPTA) and all
other drugs were purchased from Tocris Bioscience.
Unless specified, all drugswere bath applied in aCSF.Where necessary,
a brief focal application of drugs was delivered to the recorded neurons
with a quartz puffer pipette micro-manifold (QMM) fitted to a
computer-controlled pressurized drug delivery system (ALA Instru-
ments). TheQMMcomprised of 12 individual microcapillaries converg-
ing into a single tip, which had a diameter of 250m, andwas positioned
in-line with the recorded neuron at a close distance to the SCN (Fig. 2).
Under this configuration, drugs were delivered only to the SCN.
During current-clamp recordings OXA was bath applied for 3 min,
and the cell’s activity and/or resting membrane potential (RMP) were
allowed to return to, or closely to, predrug baseline levels before any
subsequent drug treatments. The effects of drug treatment on spontane-
ous firing rate (SFR), RMP, sPSCs, or mPSCs were sampled in gap-free
acquisition mode. Responses to OXA were defined by a change in RMP
that was greater than 
2 mV. The duration (min) of OXA-induced
change in RMP was measured by the time taken for the cell’s RMP value
to depart from the predrug baseline level to the time it returned to, or
close to, the baseline values. The amplitude (mV) was measured by cal-
culating 1 min averages of the RMP at predrug baseline level and at the
maximum steady-state change in RMP during OXA application. The
amplitude was obtained by subtracting these two values. Recording aCSF
(drug-free or containing drugs) solution was applied to SCN slices by
gravity-feed bath perfusion. Dose-dependent responses of SCN neurons
to 40, 60, and 80 nM OXA were performed using the puffer pipette man-
ifold, positioned close to the SCN (see above).
The mediating effects of OXA on NPY’s inhibitory actions on SCN
Per1-EGFP cells were tested by comparing the amplitude and duration of
membrane hyperpolarization to NPY in the presence and absence of bath
applicationofOXA(Fig.8).First, the responseof eachcell to twoconsecutive
brief focal applications of NPY (40 nM) was tested (Fig. 8A) using the puffer
pipette manifold placed close to the SCN. Following the recovery of the
neuron’s RMP to baseline values, OXAwas bath applied. A positive steady-
state current injection was used to counteract any hyperpolarizing effect of
OXA by returning the RMP of the cells to pre-OXA baseline levels. Then in
the presence of OXA, the cell’s response to NPY was again tested (Fig. 8).
Because SCN cells showed heterogeneity in their sensitivity to NPY, the
duration of NPY application varied from cell to cell, but to ensure com-
parability of the responses the duration/volume of its repeated appli-
cation to each neuron was identical, and this was accurately timed
through the micro 1401 mkII interface by the Spike2 software.
Groups of cells were statistically compared using ANOVA with post
hoc comparison (Sidak where repeated measures were required) or
paired/unpaired t test (SPSS version 16 and 20). For these tests, p 0.05
was considered significant. All numerical data both in text and in graphs
represent mean
 SEM. Analysis of PSC frequency and amplitude were
conducted off-line by template-based sorting using Clampfit 10.2 (Mo-
lecular Devices). Synaptic events were detected with an amplitude
threshold of 10 pA. The Kolmogorov–Smirnov (K–S) test was used for
statistical comparisons of amplitude and interevent interval distributions
of PSCs. Cumulative probability distributions were considered signifi-
cantly different with a p value 0.01 (K–S test). No overt gender differ-
ences were found in any of the electrophysiological or calcium imaging
parameters measured, so all data obtained from the male and female
mice were appropriately pooled.
SCN slice culture
On the fourth day after cull/culture preparation, SCN slice cultures were
treated with OXA (80 nM), NPY (50 nM or 200 nM), or both at circadian
time (CT) 5 (middle of the day) or CT17 (middle of the night). Treat-
ment times were calculated as projections from the light–dark cycle un-
der which mice were housed before cull, and drugs were delivered as a 1
l 1000 concentrate microdrop directly into the existing culture me-
dium. No two unilateral SCN cultures from the same slice were treated
with the same drug. Raw luminometry data were processed by subtract-
ing a 24 h running mean to remove long-term trends (baseline sub-
tracted) then smoothed with a 3 h running average (Hughes et al., 2011).
To assess phase shifts, a period for each individual tissue explant was
calculated as peak–peak duration averaged across three cycles, discount-
ing the first 24 h of data. This period was used to calculate a projected
peak phase for the cycle after drug treatments, and phase shifts were
measured as the time difference between this projected phase and actual
peak phase for that cycle. Statistically significant differences between
groups were determined using t test for 200 nM data and ANOVA with a
priori pairwise comparisons for all other comparisons; p  0.05 is re-
quired for significance.
Immunofluorescence
Six adult Per1-EGFP mice (three males and three females) were termi-
nally anesthetized with pentobarbital (80mg/kg) and they were perfused
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transcardially with 25 ml of a balanced Kreb’s
solution, followed by 25–50 ml of ice-cold 4%
paraformaldehyde in 0.1 M PBS (pH 7.4). An-
imals were perfuse fixed at ZT8–12 to maxi-
mize EGFP signal in the SCN. Prepro-orexin
knock-out mouse brains (University of Laus-
anne) were fixed using similar protocols to
those outlined. The brainswere removed, post-
fixed in the same fixative buffer for 4 h, and
stored for 2 d in 30% sucrose at 4°C. The tissues
were then flash-frozen in cooled isopentane
and cut (40 m thick) on a freezing sledge mi-
crotome (Bright Instruments). After washing
in 0.1 M PBS, the 40-m-thick brain sections
were incubated in Triton X-100 (0.1% in PBS)
for 20 min, and nonspecific protein binding
blocked with normal donkey serum (5% in
PBS containing 0.05% Triton X-100) for 30
min. Sections were incubated for 48 h at 4°C in
anti-orexin A (sc-8070; 1:1000; Santa Cruz
Biotechnology). To test for antisera specificity,
controls were performed on SCN brain sec-
tions prepared from prepro-orexin knock-out
mice or by incubating Per1-EGFP SCN sec-
tions in a working dilution of the orexin A pri-
mary antisera that had been pre-adsorbed with
5 M orexin A peptide (Tocris Bioscience)
overnight. In other control Per1-EGFP SCN
sections, anti-orexin A antisera was omitted
from the incubating solution. Following a 2 h
wash. Sections were then incubated overnight
in donkey anti-goat Alexa 568 secondary anti-
body (A-11057; Invitrogen 1:800). Although
the EGFP protein was readily detectable, for
more detailed anatomical analysis EGFP signal
was further enhanced with a rabbit anti-GFP
antibody (Invitrogen, 1:1000), followed by an
overnight incubation in donkey anti-rabbit Al-
exa 488 secondary antibody (A-21206; Invitro-
gen 1:800). All primary antibodies were diluted
in PBS containing 0.5% blocking serum and
0.05% Triton X-100. Secondary antibodies
were diluted in PBS alone. Following further
washes, sections were mounted in Vectashield
anti-fade mounting medium (Vector Labora-
tories). Stacks of digital images were captured
in series with a Leica SP5 inverted laser scanning confocal microscope
(LeicaMicrosystems). For detailed visual inspections of putative synaptic
contacts on Per1-EGFP cells by OXA-immunoreactive (OXA-ir) fibers,
3D projections of stacked confocal images (60 images per stack taken
at 63 magnification) were made using Leica LAS AF software (Leica
Microsystems).
SCN quantitative PCR for OX1 , OX2 , and Per2 genes
Quantitative real-time PCR (qRT-PCR) for OX1, OX2, and Per2 genes
was performed on SCN tissue punches collected from Per1-EGFPmice at
CT0 (n 3) and CT12 (n 3). Animals were kept in constant darkness
to eliminate light/dark time cues 1 d before tissue collection, and main-
tained in the dark during exsanguination and brain dissection. SCN slices
were cut using a vibratome (Camden Instruments) followed by mi-
cropunch dissection of the nuclei and collection into RNAlater (Sigma).
Total RNA isolated from the SCN (RNeasy micro kit; Qiagen) were re-
verse transcribed (RNA-to-cDNA Reagents; Life Technologies) for anal-
ysis by qRT-PCR. Gene analysis was performed using SYBR Green
technology (Life Technologies), andmeasured using a StepOnePlus Real
Time PCR system (Life Technologies). OX1 and OX2 transcripts were
amplified by QuantiTect primer assay (Qiagen). The following primers
tomouse Per2were used (5	 to 3	: Sense:GCCTTCAGACTCATGATGA-
CAGA; Antisense:TTTGTGTGCGTCAGCTTTGG). 18S was used as an
internal control (5	 to 3	: Sense: ACGGAAGGGCACCACCAGGA; An-
tisense: CACCACCACCCACGGAATCG). Data were analyzed using the
CT method and are expressed relative to target gene expression at
CT0. Statistical analysis was performed by a Student’s t test using Graph-
Pad Prism (GraphPad Software).
Results
Per1-EGFP neurons in the SCN are surrounded by
OXA fibers
Previous neuroanatomical studies using light microscopy report
that immunostaining for orexin is sparse to absent within the
rodent SCN (Peyron et al., 1998; McGranaghan and Piggins,
2001; Nixon and Smale, 2005). To determine the extent to which
orexin neurons innervate the mouse SCN and identify neurons
potentially innervated byOXA-containing fibers, we used immu-
nofluorescence and confocalmicroscopy and visualizedOXA im-
munoreactivity in the hypothalamus of Per1-EGFPmice. OXA-ir
fibers were present throughout the anterior hypothalamus. These
fibers were readily visualized along the dorsal and lateral bound-
aries of the SCN (Fig. 1A). To determine how the innervation of
the SCN by orexin cells mapped onto Per1-EGFP neurons, we
used anti-GFP (GFP-ir) to further enhance visualization of Per1-
Figure 1. Neurons of the SCN are surrounded by OXA-containing axons and encode for orexin receptors. A, Collapsed stacks of
confocal images taken from themiddle of the rostrocaudal axis of the SCN of Per1-EGFPmice, and immunostainedwith anti-OXA.
A, Shows OXA-ir fiber distribution (red) in the SCN with Per1-EGFP neurons (green) delineating the dorsal (dSCN) and ventral
(vSCN) anatomical structure of the SCN. a1–e3, Montage of merged and collapsed confocal image stacks of Per1-EGFP neurons
(green) and OXA-ir (red) at 63 magnification (taken from regions in A marked by white dotted boxes). Insets, a1–c1 show
orexinergic fibers (yellow) on Per1-EGFP cells (blue arrows), with a2–c2 showing separate OXA-ir axons (red) and a3–c3 Per1-
EGFPneurons. Insets,d1ande1 showexamples ofOXA-ir axonal boutons convergingon twocells that didnot contain EGFP (yellow
arrows). d2 and e2 show the same two cells with the green channel disabled, and d3 and e3 confirm the absence of EGFP in these
two cells close to OXA-ir varicotic fibers. Visual confirmation of OXA-ir varicotic fibers and terminals on Per1-EGFP cells was
performed on 3D rotated projections of optical confocal image slices before image stack collapsing (seeMaterials andMethods).B,
Confocal image showing the absence of OXA-ir staining in the SCN and adjacent hypothalamic areas of a prepro-orexin knock-out
mouse, while C andD show control SCN sections from Per1-EGFPmicewith no detectable OXA-ir staining after incubationwith (C)
OXA antibody pre-adsorbed overnightwith 5MOXApeptide, or (D)whenOXAprimary antibodywas omitted. E, F, Nonenhanced
Per1-EGFP neurons serially imaged in SCN brain sections shown in C andD, respectively. G, Expression of orexin receptor mRNA in
the SCN. Per2, OX1, and OX2 mRNA expression at CT12 (relative to 18S control) reported relative to gene expression at CT0 (*p
0.05, n 6, Student’s t test). Data shown are expressed as mean
 SEM. OX, optic chiasm; 3V, third ventricle.
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EGFP neurons in fixed SCN brain sections and coimmunola-
beled for OXA. The distribution of Per1-EGFP neurons at the
mid-coronal level of the SCN (Fig. 1A) was as previously de-
scribed (Kuhlman et al., 2003; Hughes et al., 2008). At this plane
of the SCN, OXA-ir processes innervated many sites containing
Per1-EGFP-positive and -negative (unidentified) cells. Detailed
visual inspection of 3D rotated projections of confocal image
stacks (comprised of 60 optical image slices, of 0.3 M thickness
each) at higher magnification (63) showed varicotic OXA-ir
axonal fibers around Per1-EGFP and
other cells (Fig. 1A,a1–e3). OXA-ir ax-
onal boutons converged and appeared to
delineate the soma of these cells (Fig. 1d1–
e3). In contrast, OXA-ir staining was
absent in SCN brain sections from prepro-
orexin knock-out mice (Fig. 1B), and in
brain sections from Per1-EGFP mice in-
cubated overnight with either pre-
adsorbed OXA antisera (Fig. 1C), or with
omission of OXA antisera (Fig. 1D). Fig-
ure 1, E and F, shows the nonenhanced
Per1-EGFP expression of Figure 1, C and
D, respectively. These data provide neuro-
anatomical support for orexin release in
the vicinity of Per1-EGFP neurons and
other cells in the SCN.
OX1 andOX2 receptor mRNAs are
expressed in the mouse SCN
To determine whether orexin receptors
are also expressed in the SCN, we per-
formed qPCR on mouse (n  6) SCN
brain tissue to measure the levels of
mRNA transcript encoding for OX1 and
OX2 receptors at circadian dawn and
dusk. Our results indicate that both OX1
and OX2 mRNA are expressed within the
mouse SCN, and that OX1 (t(4)  4.33,
p 0.05) but not OX2 exhibited a similar
profile to the core clock gene Per2 (t(4)
4.29, p 0.05), with a significant increase
in expression at dusk (CT12) relative to
dawn (CT0; t test; p 0.05; Fig. 1G).
OXA indirectly and directly suppresses
intracellular Ca2 levels in
SCN neurons
To investigate if and how OXA influences
SCN cellular activity, we next determined
the impact of OXA on the intracellular cy-
tosolic calcium [Ca2]i levels in SCNneu-
rons. To do this we loaded SCN brain
slices with leakage-resistant fura-2 AM
and imaged themean [Ca2]i ratio (F365/
F385 wavelengths) of multiple SCN cells
before and duringOXAapplication across
the projected day (ZT4–10) and night
(ZT16–22; Fig. 2A1–A3). Figure 2A4 il-
lustrates howmultiple SCN cells can show
robust increases in intracellular Ca2 fol-
lowing brief focal application of NMDA.
Consistent with previous work (Colwell,
2000; Ikeda et al., 2003; Irwin and Allen,
2010), the baseline cytosolic calcium levels in all SCN cells mea-
sured were significantly higher during the middle of the day
(ZT4–10, n  369) than at the middle of the night (ZT16–22;
n  333; t(645.40)  13.3, p  0.0001; Fig. 2B). Overall, bath
application of 80 nMOXAcaused significant changes (decrease or
increase) in baseline cytosolic calcium levels in 67% of these
SCN cells during the day (249 of 369 cells tested over ZT4–10),
and40%of neurons at night (133 of 333 cells tested over ZT16–
22) with remaining cells unaltered by OXA application. Of the
Figure 2. OXAmainly suppresses intracellular Ca 2 levels in SCN neurons.A, Simultaneous [Ca 2]i measurements inmultiple
SCNneurons inahypothalamic slice,with (1) recording setupwithpressurizedpuffer pipette (P)used forbrief (5 s) focal application
of NMDA; (2) SCN neurons (40) loadedwith LeakRes fura-2 AM (taken from region in (1)markedwith awhite box); (3) enlarged
single LeakRes fura-2 AM loaded SCN neuron; (4) representative SCN neurons showing transient [Ca 2]i increase in response to a
focal application of NMDA (200M, 5 s; duration black bar at top) in the late day (ZT10).B, Overall summary ofmeasured baseline
[Ca 2]i level in SCN cells showing significantly higher [Ca
2]i value during the day (ZT4–10) than at night (ZT16–22). During the
day,OXA (80nM) significantly suppressed (C,D;n172/249) or elevated (E;n77/249) thebaseline [Ca 2]i ratio in69and31%
of responsive SCN neurons, respectively. At night, OXA decreased (F ) the baseline [Ca 2]i ratio in 97% (n 129/133) of respon-
sive SCN neurons while increasing this ratio in only 3% (n 4/133) of cells (data not shown). This nighttime effect of OXA on
cytosolic calcium levels in SCN neuronswas insensitive to coapplication of gabazine and CGP5585 (K ), GABAA, and GABAB receptor
antagonists, respectively, but was abolished when OXA receptor antagonist SB33487 was coapplied with OXA (G). In contrast, in
the day, gabazine abolished OXA’s suppression of cytosolic calcium levels in SCN cells (H ), but not its induced elevation (J ) of the
ratio.G–I, In the presence of gabazine and SB33487 the cells showed an acute increase in their cytosolic calcium levels in response
to a 200M focal application (5 s) of NMDA. L, Summary of OXA effects on [Ca 2]i level in SCN cells over the day and at night. All
data shown are expressed as mean
 SEM; *p 0.05,***p 0.0001. Number of cells measured is shown in brackets. OX, optic
chiasm; 3V, third ventricle; P, tip of the pressurized puffer pipette manifold.
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responsive cells tested during the day, most (172/249 cells; 69%)
significantly reduced cytosolic calcium levels to OXA application
(t(171) 8.32, p 0.0001; Fig. 2C,D,L), with the remaining cells
(77/249) showing significant elevation in intracellular calcium
levels to OXA (t(76)9.97, p 0.0001; Fig. 2E, J,L). At night,
the predominant response to OXA (80 nM) was a significant re-
duction in the cytosolic calcium level (129 of 133OXA responsive
cells; 97%; t(128)  12.34, p  0.0001; Fig. 2F,K,L), with only a
minority of cells (4/133) showing significant elevation in [Ca2]i
(t(3)4.59, p 0.05; Fig. 2L). Hence, there is a significant time
of day effect on the suppressive (day: 47% of cells tested; night:
39%) and activational (day: 21% of all cells tested; night: 3%)
actions of OXA on the mean cytosolic calcium levels in SCN neu-
rons.Pretreatmentwithanorexin receptor antagonist SB334867 (10
M) prevented cells from changing their intracellular calcium
levels to subsequent treatment with OXA (regardless of time of
day), but did not block cytosolic calcium responses to focal ap-
plication of the glutamatergic agonistNMDA(200M for 5 s; Fig.
2G,I). Therefore, actions ofOXAon intracellular calciumof SCN
cells require activation of orexin receptors.
Intriguingly, most investigations of OXA on cytosolic calcium
in neurons report that OXA elevates intracellular Ca2, an out-
come interpreted as a consequence of OXA depolarizing neurons
(Kohlmeier et al., 2008). Many SCN cells are GABAergic (Moore
and Speh, 1993; Buijs et al., 1994; Castel and Morris, 2000) and
functional GABAA and GABAB receptors are present in the SCN
(Strecker et al., 1997; Itri and Colwell, 2003; Moldavan et al.,
2006; Irwin and Allen, 2009). To determine whether the suppres-
sive actions of OXA involve inhibitory GABA signaling, OXA-
responsive cells were retested for the responses to this
neuropeptide in the presence of gabazine and CGP55845, antag-
onists of GABAA and GABAB receptors, respectively. During the
day, blockade ofGABAergic signaling abolished all ofOXA’s sup-
pression of intracellular calcium in SCNcells (n 90 cells tested).
Figure 2H shows a cell that reduced intracellular Ca2 to OXA,
but not when OXA was coapplied with gabazine. Such treatment
with gabazine had no effect on the subset of cells that elevated
cytosolic calcium levels in response toOXA (Fig. 2J). Subsequent
focal application ofNMDA (200M for 5 s) caused a robust acute
rise in cytosolic calcium levels in all daytime SCN cells treated
with gabazine (Fig. 2H). In contrast to this reliance on GABA
signaling through GABAA receptors (GABA-GABAA receptor
signaling) during the day, the suppression of intracellular cal-
cium in SCN cells by OXA at nighttime was not altered when
pretreated with 20 M gabazine (n 42; Fig. 2K). Since GABAB
receptors are also present in the SCN region (Francois-Bellan et
al., 1989; Gribkoff et al., 2003), we also determined whether
blockade of GABA-GABAB receptor signaling influenced OXA’s
nighttime actions. Pretreatment with the GABAB receptor antag-
onist CGP5584 (10 M) did not affect subsequent responses to
OXA (n  48) (Fig. 2K). This indicates that OXA’s suppressive
actions on cytosolic calcium levels of SCN cells require functional
GABAA receptor signaling during the day, while at night neither
GABAA nor GABAB receptor signaling is required for OXA’s ac-
tions. Further, these data demonstrate that the elevations in in-
tracellular calcium evoked by OXA are unaffected by blockade of
GABAergic mechanisms.
In summary, the cytosolic calcium experiments establish that
OXA acts principally to suppress rather than elevate levels of
intracellular calcium, thereby indicating that OXA is unlikely to
depolarize the majority of SCN cells, or that if it does, then this
occurs viamechanisms that do not increase intracellular calcium.
Since intracellular Ca2 levels are associated with the intrinsic
electrical state of SCN neurons (Diekman et al., 2013), these re-
sults suggest that OXA should mostly suppress SCN neuronal
activity.
Day–night differences in the actions of OXA on SCN neurons
To determine whether SCN neurons responsive to OXA contain
clock genes and to evaluate how this neuropeptide alters the in-
trinsic electrical properties of SCN neurons, we used epifluores-
cence and performed targeted whole-cell current-clamp
recordings from identified Per1-EGFP (n 162) neurons in SCN
brain slices (n 55).We tested how bath application of OXA (80
nM for 3 min to achieve a steady-state concentration in the bath)
altered the bioelectric activities [RMP, Rinput, and SFR of action
potentials (APs)] of Per1-EGFP neurons. Since the electrical ac-
tivity of SCN neurons varies across the circadian cycle (Brown
and Piggins, 2007; Colwell, 2011) and can influence how these
cells respond to neurochemicals (Piggins et al., 1994), we re-
corded and compared OXA’s action across a 10 h epoch of the
projected day (ZT2–12) and 6 h epoch of the projected night
(ZT16–22). Consistent with previous reports (Kuhlman et al.,
2003; Belle et al., 2009; Scott et al., 2010), SCN Per1-EGFP neu-
rons were more active during the day than the night. Significant
day–night differences were seen in mean RMP (40.3
 0.9 mV
vs49.1
 1 mV; t(155.62) 13.78, p 0.001) and Rinput (1.9

0.1 G vs 1.5 
 0.03 G; t(102.43)  6.97, p  0.001). With the
exception of the middle to late projected day (ZT6–9), when
some Per1-EGFP neurons stop generating APs by depolarization
blockade (Belle et al., 2009; Scott et al., 2010), daytimePer1-EGFP
cells showed elevated SFR compared with the low to moderate
frequencies recorded at night (2.9 
 0.3 Hz vs 1.7 
 0.2 Hz;
t(83.46) 4.3, p 0.001).
Across the projected circadian cycle, the majority of Per1-
EGFP SCN neurons tested responded to OXA (119/162; 73%),
with inhibitory hyperpolarizing actions predominating (100/119
responsive cells; 84%; Fig. 3A,C,E). Further, OXA-induced hy-
perpolarizations were significantly longer in duration at night
than those elicited during the day (54.8
 4.4 min vs 14.2
 1.5
min; t(72.33)  13.43, p  0.0001). In the remaining 16% of
responsive Per1-EGFP cells (19/119), OXA caused excitation
with associated significant increase in AP discharge during the
day (t(18)11.99, p 0.0001; Fig. 3G,I), but not at night. This
tendency for OXA to suppress excitability of SCN neurons was
also seen in our previous in vitro extracellular recordings (Brown
et al., 2008), and in preliminary investigations we have also ob-
served this in in vivo extracellular recordings (data not shown).
Independent of the polarity of the response or time of day, OXA-
responsive Per1-EGFP SCN cells did not respond to this neuro-
peptide when tested in the presence of the OXA receptor
antagonist SB334867 (10M; Fig. 3B; day and F; night, for exam-
ple); thus indicating the dependence of OXA responses in the
SCN on orexin receptor activation.
Mechanisms of OXA signaling in SCN Per1-EGFP neurons
in vitro
Hyperpolarizations evoked by OXA during the day were not as-
sociated with changes in Rinput (1.9 
 0.1 G vs 1.8 
 0.2 G;
paired t test, p 0.05), whereas at night, Rinput was significantly
reduced (1.6
 0.1 G vs 0.8
 0.1 G; t(29) 17.12, p 0.001,
paired t test). This indicates day–night differences in the potential
contribution of K conductances, and presynaptic and postsyn-
aptic mechanisms to the hyperpolarizing actions of OXA. To
evaluate contributions of presynaptic and postsynaptic mecha-
nisms to these actions of OXA, cellular responses of orexin-
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responsive neurons were retested to this neuropeptide in the
presence of TTX-containing aCSF. TTX concentrations (0.5–1
M), that block most voltage-dependent sodium channel con-
ductances and hence AP-dependent synaptic communication,
abolished inhibitory responses to OXA during the day (8 of 8
responsive cells; Fig. 3C,D), but not at night (0 of 8 responsive
cells; Fig. 3E). Indeed, during the day when TTX was continu-
ously bath applied before OXA treatment to a different cohort of
neurons, none of these cells tested hyperpolarized to OXA (0 of 7
cells tested; data not shown). This indicates that during the day,
OXA recruits presynaptic mechanisms to indirectly suppress
neuronal activity in the SCN, whereas at night, it acts directly to
hyperpolarize the cells.
Similar to the direct hyperpolarizing actions of OXA at night,
daytime SCNneurons depolarized byOXA given in control aCSF
also depolarized to OXA when AP-dependent communication
was blocked by pretreatment with TTX (Fig. 3G,H). These find-
ings establish a profound day–night difference in the actions of
OXA in the SCN and suggest that stimulation of orexin receptors
during the day activates indirect inhibitory neurotransmission
mechanisms, whereas at night this stimulation of orexin recep-
tors directly inhibits SCN neuronal activity.
To investigate whether OXA applied directly to the SCN
would also inhibit Per1-EGFP neurons, we focally applied 40, 60,
and 80 nM OXA to daytime recorded Per1-EGFP cells, by a pres-
surized puffer pipette placed close to the SCN (Fig. 2A1). This
permits three consecutive brief pulses (35 s duration each) of
OXA to be quickly delivered to the SCN, allowing shorter recov-
ery time for the cells between each OXA dose than with bath
application (Fig. 4A). As shown in Figure 4, A and B, focal appli-
cation of OXA causes suppression of RMP and SFR of SCN cells
(n 4) in a dose-relatedmanner (RMPamplitude: F(2,6) 54.92,
p 0.001; and duration: F(2,6) 467.21, p 0.001; SFR: F(2,6)
8.22, p  0.05). Analysis from four Per1-EGFP neurons tested
with these doses of OXA showed that the suppressive action of
OXA (lowering of RMP and SFR) was not different at 40 and 60
nM doses (p 0.05). In contrast, 80 nM OXA produced suppres-
sion in baseline RMP (p  0.001) and SFR (p  0.05) that was
significantly larger than effects seen with 40 nM OXA. Focal ap-
plications of aCSF alone had no effect on membrane excitability
in these cells (data not shown).
The direct depolarizing actions of OXA on central neurons in
many brain sites are well described (Kukkonen and Akerman,
2005; van den Pol and Acuna-Goycolea, 2005; Eriksson et al.,
2010), whereas its inhibitory effects are less frequently reported
and poorly understood. Therefore, we subsequently focused on
the mechanisms of OXA-induced hyperpolarization.
GABAergic signaling is differentially recruited from day
to night
As revealed above, the TTX sensitivity of OXA-induced hyper-
polarization of Per1-EGFP neurons during the day indicates an
Figure 3. OXA directly activates and indirectly suppresses Per1-EGFP neuronal activity dur-
ing the day. A, Typical inhibitory response of an SCN Per1-EGFP cell to bath application of OXA
during the projected day caused membrane hyperpolarization and suppression of AP firing. A,
B, F, Whole-cell recordings from Per1-EGFP neurons during the day (A, B) and at night (F )
showing that the orexin receptor antagonist, SB334867 (10M), had no effect on membrane
excitability, but prevented the hyperpolarizing actions of OXA. C–E, TTX (0.5M), given to cells
responsive to OXA in control aCSF (C), abolished inhibitory responses to OXA during the day (D),
but not at night (E; showing two cells hyperpolarizedwithOXA in thepresenceor absenceof TTX
in the aCSF). This establishes a clear day–night difference in the actions of OXA in the SCN, and
shows that stimulation of orexin receptors during the day activates indirect AP-dependent
inhibitory neurotransmission mechanisms, whereas at night this stimulation of orexin recep-
tors directly inhibitsPer1-EGFPneuronal activity.G,H, OXA causedmembranedepolarization in
SCN Per1-EGFP neurons recorded during the day (G), which persisted when OXAwas coapplied
with TTX (1M) in the bath (H ), indicating postsynaptic (direct) excitation. I, In the absence of
TTX, this depolarizing effect of OXA on Per1-EGFP was accompanied with a significant increase
in firing rate. B, D, H, Consecutive traces from A, C, and G, respectively. **p 0.01. All data
shown are expressed as mean
 SEM. Number of cells measured is shown in parentheses.
Figure4. BlockadeofGABA receptors abolishes the suppressive actions ofOXAonPer1-EGFP
cells during the day but not at night. A, Representative consecutive whole-cell recordingmade
from a Per1-EGFP neuron at ZT4, showing dose-related hyperpolarizing responses to focally
applied (duration 35 s) 40, 60, and 80nMOXA.B, Summary of responses from fourPer1-EGFP
cells to focally applied OXA doses. C, E, Whole-cell recordings from Per1-EGFP neurons showing
OXA causing membrane hyperpolarization and suppression of AP firing in the day (C) and at
night (E). C, D, Cotreatment of Per1-EGFP neurons suppressed by OXA in control aCSF (C) with
the GABAA receptor antagonist, gabazine (20M), blocked the hyperpolarizing actions of OXA
during theday (D).E, In contrast, cotreatment ofPer1-EGFP cellswithgabazine (20M) and the
GABAB receptor antagonist CGP55845A (10M) at night did not prevent OXA-induced hyper-
polarization in these cells. F, Typical membrane potential response of Per1-EGFP cells to a brief
focal application of gabazine (20M in a puffer pipette for 20 s) during OXA bath application in
the day,which transiently blockedOXA-induced hyperpolarization in these cells. This reinforces
the reliance of OXA on functional GABAA receptor signaling during the day to suppress electrical
activity of Per1-EGFP cells. D is a consecutive trace from C. *p  0.05. All data shown are
expressed as mean
 SEM.
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underlying presynaptic mechanism. In
line with the OXA-induced suppression
of intracellular calcium, the inhibitory
daytime actions of OXA on Per1-EGFP
neurons were blocked (16 of 16 OXA-
responsive cells) by coapplying OXA with
the GABAA receptor antagonist gabazine
(20M; Fig. 4D). In contrast, at night, nei-
ther coapplication of gabazine (20 M; 0
of 8 responsive cells) nor the GABAB re-
ceptor antagonist, CGP55845A (10 M; 0
of 7 responsive cells), prevented OXA’s
robust hyperpolarizing effect on Per1-
EGFP neurons (Fig. 4E).
To establish whether daytime applica-
tion of OXA-evoked GABA release within
the SCN (as opposed to extraSCN areas),
gabazine (20 M) was focally applied in
the SCN (20 s with a puffer pipette; diam-
eter 250 M) in the presence of bath-
appliedOXA. As shown in Figure 4F, brief
blockade of the GABAA receptor by gaba-
zine (n  6) in the SCN abolished the
hyperpolarizing action of OXA on Per1-
EGFP cells (6 of 6 cells). Together, these
findings confirm that during the day,
functional GABAA receptors are neces-
sary for OXA to inhibit and alter the in-
trinsic state of SCN Per1-EGFP neurons,
whereas at night, neither GABA-GABAA
nor GABA-GABAB receptor signaling is
necessary for the hyperpolarizing actions
of OXA.
These results demonstrate that OXA
engages neural networks intrinsic to the
SCN in a dose- and time-dependent man-
ner to suppress Per1-EGFP-expressing
SCN clock cells.
OXA increases sPSCs andmPSCs in SCN neurons during
the day
We next assessed the effects of OXA on the frequency and ampli-
tude of sPSCs and mPSCs in voltage-clamp recordings of Per1-
EGFP neurons. Measurement of sPSCs and mPSCs frequency
assesses AP-dependent and -independent synaptic vesicle release,
respectively, and allows us to determine whether OXA can also
act directly on presynaptic terminals to cause the release of neu-
rotransmitters in the absence of presynaptic APs (quantal release;
recorded as mPSCs). Bath application of OXA produced an in-
crease in the frequency and amplitude of sPSCs in65%of Per1-
EGFP cells (25/39 cells recorded; Fig. 5A,b2,C,D). In these
responsivePer1-EGFP cellsOXA significantly increased themean
sPSC frequency from 2.2
 0.2Hz (basal) to 6.4
 0.8Hz (t(24)
11.25, p 0.001; paired t test) and the amplitude from 45.6

2.1 pA (basal) to 76.2
 9.4 pA (t(24)8.77, p 0.05; paired t
test; Fig. 5A). Pretreatment with the orexin receptor antagonist
SB334867 abolished these actions of OXA (Fig. 5E,F), indicating
that they are mediated by activation of orexin receptors.
Under our intracellular recording conditions (20 mM KCl-
filled pipettes) Cl currents have a reversal potential of approx-
imately 43 mV, and thus both GABAA and AMPA/NMDA
currents appear as inward currents at the holding potential that
we used (70 mV) (Itri and Colwell, 2003). Therefore, we used
receptor-selective antagonists to investigate whether the OXA-
induced sPSCs were GABAergic or glutamatergic. In all OXA-
responsive Per1-EGFP cells tested, OXA-induced sPSCs were
insensitive to bath application of the glutamatergic receptor an-
tagonists, AP5, CNQX, andNBQX (0 of 10 cells; data not shown).
In contrast, these OXA-sensitive spontaneous events were com-
pletely abolished by bath application of gabazine (20 M for 5
min; 10 of 10 cells; Fig. 5b3), indicating that they were GABAA
receptor-mediated IPSCs. The rise time to peak of these sponta-
neous IPSCs was 2.9 
 0.3 ms and the time constant decay was
14.7
 0.5 ms, values that are consistent with previous observa-
tions using similar recording conditions to study GABAA receptor-
mediated spontaneous IPSCs in SCN neurons (Itri and Colwell,
2003; Itri et al., 2004).
Bath application of TTX (0.5 M) significantly reduced or
abolished the sPSCs inOXA-responsivePer1-EGFPneurons (9 of
9 cells; Fig. 5A,b5; nowmeasured asmPSCs). However, as shown
in Figure 5, A, b6, and b7, in the presence of TTX OXA signifi-
cantly induced mPSCs frequency in the cells (t(8)  4.8; p 
0.01). These OXA-induced mPSCs were abolished by gabazine
(20 M; tested in four cells), demonstrating that they were
GABAergic events (Fig. 5A,b8). Therefore OXA significantly in-
creases presynaptic release of GABA onto Per1-EGFP neurons,
which leads to significant inhibition of these cells. A similar ac-
tion of OXA has been reported in dorsal raphe cells (Liu et al.,
2002).
Figure 5. OXA increases PSCs in Per1-EGFP cells during the day. A, Summary of results from all Per1-EGFP neurons showing an
increase in sPSC amplitude and frequency (n 25 cells) and an increase in mPSC frequency (n 9 cells) with OXA. Gabazine (20
M) completely abolished all OXA-induced mPSCs (n 4 cells) and sPSCs (n 10 cells), demonstrating that they are GABAA
receptor mediated. B, Examples of traces from two individual Per1-EGFP cells (voltage clamped at70mV; b1–b6 for cell1 and
b7,b8 for cell2)with top traces showing an increase in PSC frequency and amplitude following bath application of 80 nMOXA (b2).
Bath application of gabazine (20M) blocked all PSC and OXA-induced effects (n 10; b3), showing that they are GABAergic.
After prolongedwashout (b4 ), bath applicationof TTX (0.5–1M) significantly reducedor abolishedall PSCs (n6;b5), but bath
application of OXA in TTX (n 6) induced mPSCs (b6 ). This shows that OXA can also induce PSCs in an impulse-independent
manner. b7, b8, Example of traces from the second Per1-EGFP cell showing elevated mPSC frequency with OXA (b7 ), which was
abolishedbygabazine (b8). At each condition, the tracesdisplay twoconsecutive10 s episodes recorded fromtypicalOXA-sensitive
neurons. C, D, Normalized cumulative distributions of PSC interevent intervals and amplitude for the cell in b1–b6 before and
during OXA application (data taken for 2min from each condition; p 0.001; K–S test). E, F, In all cases (n 5), coapplication of
OXAwith SB334867 abolished all responses in orexin-sensitive cells. Recordingswere performed in the presence of AP5, CNQX, and
NBQX, blockers of NMDA/AMPA/kainate-type glutamate receptors. *p 0.05, **p 0.01. All data shown are expressed as
mean
 SEM. Number of cells measured is shown in parentheses.
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OXA hyperpolarizes SCN cells at night by opening leak
K channels
At night, OXA-induced hyperpolarization persists even when
AP-dependent synaptic communication and GABA-GABAA re-
ceptor signaling are impaired (with TTX and gabazine, respec-
tively), indicating that presynaptic mechanisms do not overtly
contribute to these nocturnal inhibitory effects of OXA. To es-
tablishwhetherClwas involved inOXA’s hyperpolarizing post-
synaptic actions at night, we substituted gluconate for equimolar
Cl in the intracellular pipette solution in current-clamp record-
ings. This sets the reversal potential for Cl near zero, eliminat-
ing Cl conductances in these cells. Under this condition, the
likely hyperpolarizing force capable of inhibiting the cells to this
degree is produced by the K channels. Indeed, recording with
intracellular pipette solution containing 130 mM KCl did not
prevent the robust hyperpolarizing effects of OXA in all cells
tested (p  0.05 for amplitude of hyperpolarization in KCl vs
K-gluconate; n  6; Fig. 6A). This establishes that K, but not
Cl, currents are responsible for this effect of orexin. OXA-
induced hyperpolarization was also unaffected by fixing intracel-
lular Ca2 at90 nMwith a BAPTA-Ca2mixture (n 5), or in
the presence of a low Ca2/high Mg2 aCSF (n 7; Fig. 6B,C).
Blockage of voltage-gated calcium channels with cadmium (30
M; Cloues and Sather, 2003; Pitts et al., 2006) also had no effect
on OXA-induced inhibition at night (n
4: data not shown). Thus, dialyzing the
neurons with 10 mM BAPTA (a rapid
Ca2 buffer) coupled with 2 mM Ca2
(thereby clamping cytosolic Ca2) did
not preventOXA’s action. Together, these
results show that neither Ca2 entry, nor
its release from intracellular stores, is crit-
ical for OXA’s hyperpolarizing action. This
strongly indicates that Ca2-activated K
channels, which in Per1-EGFP cells can show
increased conductance at night (Pitts et al.,
2006), are unlikely to be involved in
OXA’s nocturnal actions.
Previously, OXA has been shown to
increase excitability of thalamic cells by
suppressing the activity of leak K con-
ductance (Govindaiah and Cox, 2006).
Considering the robust and long-lasting
hyperpolarizing effect we observe during
nighttime administration ofOXA, and the
very slow onset, and postsynaptic nature
of this response, we tested whether OXA
was activating background leak K chan-
nels to hyperpolarize SCN neurons at this
time.We first investigated this in current-
clamp recordings to see if the blockade of
leak K channels prevented OXA’s inhib-
itory action. We challenged OXA respon-
sive neurons with quinine or quinidine
(500 M), two broad-spectrum leak K
channel inhibitors (Lotshaw, 2007). Both,
quinine (RMP: F(2,10) 25.55, p 0.001;
Rinput: F(2,10)  17.47, p  0.01, n  6;
Figure 6D,E) and quinidine (RMP: F(2,6)
 50.41, p 0.001; Rinput: F(2,6) 25.06,
p  0.001, n  4; data not shown) re-
versed OXA-induced hyperpolarization,
returning the RMP (post hoc tests for qui-
nine: control vs OXA, p  0.01; OXA vs OXA  quinine, p 
0.01; quinidine: control vs OXA, p 0.01; OXA vs OXA quin-
idine, p 0.05) and Rinput (post hoc tests for quinine: control vs
OXA, p  0.01; OXA vs OXA  quinine, p  0.01; quinidine:
control vs OXA, p  0.05; OXA vs OXA quinidine, p  0.05)
values to near baseline levels, causing some neurons to fire APs
(Fig. 6D,E). This is consistent with the idea that leakK channels
are important for OXA’s hyperpolarizing effects at night.
To define the nature of this leak K current, we performed
subsequent experiments in voltage-clamp recordings using slow
ramps of voltage in the range from 0 to120 mV (see Materials
and Methods; Fig. 6F). In the presence of TTX (1–2 M), OXA
(80 nM) caused a change in the current–voltage relationship (Fig.
6F). The net current triggered by OXA (obtained by subtracting
baseline I–V from OXA I—V; Fig. 6G), had a reversal potential
near93 mV (expected Ek102 mV), was almost linear, and
was potently inhibited both by quinine (n  11; Fig. 6G) and
quinidine (n 5; data not shown). Together, these observations
implicate an OXA-activated current flowing through leak K
channels to cause membrane inhibition. At night, Per1-EGFP
neurons typically rest, on average, approximately47 mV (Belle
et al., 2009). At this voltage range (approximately47mV),OXA
significantly increased (t(10) 12.46; p 0.001, paired t test) the
hyperpolarizing background leak K conductance by 40% in
Figure 6. OXA causes direct membrane hyperpolarization and suppression of Per1-EGFP neuronal activity at night. A–C, Bath
application of OXA hyperpolarized Per1-EGFP neurons, and in all cells this hyperpolarization was significantly larger in duration
(50 min) at this circadian phase than during the day. A, B, OXA-induced suppression of Per1-EGFP cells persisted when (A)
intracellular K-gluconate was substituted with equimolar KCl solution; (B) intracellular Ca 2 solution was clamped at90 nM
withBAPTA-Ca 2mixture, preventingCa 2mobilization from intracellular stores; and (C)whenCa 2 influxwaspreventedwith
low Ca 2/highMg 2 extracellular solution.D, Bath application of quinine prevented OXA-hyperpolarizing effect. E, Summary of
results obtained from six current-clamp cells where OXA-induced membrane hyperpolarization and accompanied reduction in
Rinput were blockedwhen OXAwas coappliedwith quinine. F, I–V relationship during baseline (black trace) and in the presence of
OXA (gray trace) obtained by slowly ramping the membrane voltage (see Materials and Methods and inset). G, Net OXA current
obtained by subtracting OXA I–V from control I–V (black trace), with quinine potently inhibiting this OXA-induced current (gray
trace). **p 0.01. Data are expressed as mean
 SEM. Number of cells measured is shown in parentheses.
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responsive neurons (estimated by the size
of the quinine-sensitive current). There-
fore, activation of leak K channels forms
part of the mechanism by which OXA
causes prolonged suppression in electrical
activity of Per1-EGFP neurons at night.
OXAmodulates the acute and phase-
resetting actions of NPY on
SCN neurons
Previous research has implicated inhibi-
tory signaling as conveying arousal-
promoting (or nonphotic) time cue
information to the SCN (Smith et al.,
1989; Cutler et al., 1998; Gribkoff et al.,
1998). An important source of nonphotic
input to the SCN is the GHT (Harrington,
1997) with NPY being an important sig-
naling molecule in this pathway. During
the day, NPY potently inhibits SCN neu-
ronal activity, suppresses Per1 expression,
and resets the SCN clock (Medanic and
Gillette, 1993; Shibata and Moore, 1993;
van den Pol et al., 1996; Fukuhara et al.,
2001; Maywood et al., 2002). Since the
predominant action of OXA on Per1-
EGFP SCN neurons is also suppression, we next asked whether
daytime application of OXA phase advances the SCN molecular
clock. We therefore assessed the phase of PER2::LUC rhythms in
SCN brain slice cultures treated with OXA (80 nM), NPY (50 nM
or 200 nM), or both in themiddle of the circadian day (CT5).NPY
at 200 nM evoked large (6 h) phase advances in the timing of
peak PER2::LUC expression, whichwere significantly different to
the effects of control protocols (t(6)  2.89, p  0.05; Fig. 7A).
Low-dose NPY (50 nM) or OXA (80 nM) alone did not alter the
timing of peak PER2::LUC (net shift relative to controls of0.9 h
and approximately 0.2 h, respectively; both p  0.05). How-
ever, coapplication of OXA (80 nM) and NPY (50 nM) induced
phase advances (2 h) that were significantly larger than those
measured with NPY alone (F(1,53) 4.1, p 0.05) or in controls
(F(1,53)  10.1, p  0.01; Fig. 7B,C). This indicates that OXA
signaling in the SCN enhances the phase-shifting capacity ofNPY
on core molecular clock rhythms. Further, this shows that al-
though OXA on its own modulates the electrical activity and
intracellular Ca2 of themajority of SCNneurons tested over the
day, this neuropeptide does not itself evoke measurable phase
shifts of the SCN.
Nonphotic stimuli have much less prominent phase-shifting
effects during the subjective night, and to test whether these re-
setting actions of OXA andNPY also show phase dependence, we
assessed shifts in PER2::LUC expression following treatments
with OXA (80 nM), NPY (50 nM), or OXA and NPY given at the
middle of the projected night (CT17). Neither neuropeptide
alone nor in combination produced phase advances; indeed, only
nonsignificant small phase delays were observed (Fig. 7B). This
indicates that although OXA has long-lasting suppressive effects
on electrical activity and intracellular Ca2 of SCN neurons at
night, these acute effects do not detectably influence the phase of
the SCNmolecular clock during the circadian night. Collectively,
these data demonstrate that during the subjective day, OXA sig-
nificantly augments the phase-resetting actions of a subthreshold
dose of NPY, while at night, neither neuropeptide alone or in
combination can significantly reset the SCN clock.
SinceOXA enhanced the daytime resetting actions ofNPY, we
next investigated whether OXA influences the inhibitory actions
of NPY on SCN neurons. We performed targeted current-clamp
recordings from SCN Per1-EGFP cells in the day and compared
their responses to NPY (two 40 nM brief applications by puffer
pipette) both alone and in the presence of bath-applied OXA (80
nM). To allow for appropriate comparison between NPY’s ac-
tions alone and in the presence of bath-applied OXA, the follow-
ing recording and drug treatment procedures were used (Fig.
8A). First, the cell’s response to two consecutive brief focal appli-
cations of NPY (40 nM) was tested, allowing for full recovery of
the cell’s RMP between NPY applications. OXA was then bath
applied until the cell’s response to this neuropeptide reached
maximal value and plateaued. Next, before the cell’s response to
NPYwas retested in the presence of OXA, the RMP of the neuron
was returned to its initial baseline value (beforeOXAapplication)
by manually passing a steady-state current (e.g., indicated by a
ve current in Fig. 8A). This ensures that most of the mem-
brane’s ionic conditions are restored to baseline values, allowing
for appropriate comparisons with previous NPY applications
(when OXA was not present). This steady-state current injection
was applied in conjunction with the puffer application of NPY
and removed only following the full recovery of the cells to NPY
(Fig. 8A). Electrical recordings from SCN Per1-EGFP cells that
showed sensitivity both to OXA and NPY (15 of 34 neurons
tested) revealed that the suppressive actions of NPY (40 nM) on
these cells were significantly larger in the presence of OXA (80
nM; n 15; Fig. 8A,B). Both the amplitude (NPY 3.9
 0.5
mV;NPYOXA8.5
 1.3mV; t(14)3.34, p 0.01) and
duration (NPY  1.3 
 0.2 s; NPY  OXA  13.3 
 2.7 s;
t(14)4.33, p 0.01) of NPY-inducedmembrane hyperpolar-
ization significantly increased in the presence of OXA compared
with NPY alone (Fig. 8A,B). Similar observations were seen in 5
of the 19 cells that showed no overt responsiveness to OXA (data
not shown).
We next investigated if GABA-GABAA receptor signaling is
recruited by OXA to potentiate these acute actions of NPY on
Figure 7. OXA augments NPY’s phase-shifting capacity of SCN clock neurons. A, During the day NPY (200 nM) significantly
advanced the peak phase of PER2::LUC rhythms in the SCN in vitro. B, Summary of PER2::LUC phase responses of cultured SCNs to
treatment with OXA (80 nM), subthreshold NPY (50 nM), or both OXA and subthreshold NPY during the day (CT5) and night (CT17).
Neither OXA nor subthreshold NPY alone produced phase shifts that are significantly different to controls during either the
projected day or night. OXA and NPY combined, however, result in significant phase advances during the day, but not at
night. C, Example luminometry traces of PER2::LUC expression in cultured SCNs treated at CT5 on day 4 in culture with either
control (solid blue line) or OXA and 50 nM NPY combined (dashed red line). Note that the peak times for both traces are in
phase before treatment but that following treatment the OXA and NPY trace is significantly phase advanced. *p 0.05 and
**p 0.01 denote significance (t test or ANOVA with a priori pairwise comparison). Number of brain slices used for each
condition are shown in parentheses. Data shown in A and B are mean
 SEM.
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SCNneurons. To do this, we first tested the cell’s response toNPY
alone, then toNPY andOXA, as described above. But in addition,
to see if GABAA receptor blockade prevents OXA’s facilitation of
NPY’s suppressive action, we also tested the effect of NPY in the
presence of bath coapplication of gabazine and OXA. Indeed, as
shown in Figure 8, A and B (n  5 cells), blockade of GABAA
receptors with gabazine abolished the potentiating effect of OXA
on NPY’s inhibitory action on Per1-EGFP neurons (hyperpolar-
ization amplitude: NPY alone vs NPYOXA vs NPYOXA
Gabazine, F(2,8) 34.93, p 0.001; duration: NPY alone vs NPY
OXAvsNPYOXAGabazine, F(2,8) 40.38, p 0.001; see
Fig. 8B for illustration of group mean comparisons). Together,
these results demonstrate that in the SCN OXA acts via GABA-
GABAA receptor signaling to facilitate the phase-shifting and
electrical silencing capacity of NPY.
Discussion
Here we show a new atypical influence of orexin signaling over
SCN clock cell activity and timekeeping. Physiological investiga-
tions in vitro demonstrate clear day–night differences in thepolarity
of SCN neuronal responses to orexin. Across the projected circa-
dian cycle, most orexin-responsive SCN neurons respond to
orexin by suppressing baseline intracellu-
lar calcium levels ([Ca2]i) and neuronal
activity. Actions of this neuropeptide are
prevented by blockade of orexin recep-
tors, but local inhibitory circuits within
the SCN are differentially recruited by
orexin from day to night. During the day,
orexin presynaptically modulates inhibi-
tory GABA-GABAA receptor signaling,
while at night, orexin’s suppressive ac-
tions do not require recruitment of either
GABA-GABAA or GABA-GABAB recep-
tor signaling mechanisms. Instead, these
nighttime inhibitions to orexin arise
through direct postsynaptic activation of
leakK currents andhyperpolarization of
SCN neurons. Functionally, orexin en-
hanced the phase-advancing actions of
NPY, another neuropeptide implicated in
conveying arousal information to the
SCN. This modulation of peptidergic sig-
naling is observable at the single neuron
level where orexin potentiates inhibitory
effects of NPY during the day. Thus,
orexin in the SCN ismostly inhibitory and
functions like other neural signals impli-
cated in relaying arousal information to
the SCN clock.
Direct orexin signaling in the brain is
commonly considered excitatory (Eriksson et
al., 2010) and can elicit depolarization, in-
creased AP firing, and elevations in
[Ca2]i. However, in the SCN, these ac-
tions of orexin were rarely observed, espe-
cially at night. Even during the day, direct
excitatory actions of orexin on [Ca2]i
and Per1-EGFP neuronal activity were
observed in only a minority of OXA-
responsive cells, whereas most OXA-
responsive Per1-EGFP neurons in the
SCN were indirectly inhibited by OXA.
Since the majority of SCN neurons are
GABAergic (Antle and Silver, 2005), this indicates a possible
pathway through which orexin excitation of some SCN neurons
increases inhibitory GABAergic tone within the SCN overall.
In other parts of the hypothalamus and brainstem, orexin
excites local GABAergic interneurons to presynaptically regulate
GABAergic transmission (van den Pol et al., 1998; Liu et al., 2002;
Eriksson et al., 2004;Ma et al., 2007). In our daytime SCN record-
ings, focal application of gabazine into the SCN blocked orexin’s
suppression of the Per1-EGFP neurons, thereby showing that
orexin can increase the frequency of GABA-mediated IPSCs, pre-
sumably by increasing GABA release from local SCN neurons.
Indeed, across the projected day, we found that orexin evoked
increases in GABAA receptor-mediated inhibitory events both in
an impulse-dependent and independent manner with gabazine
preventing orexin from reducing [Ca2]i. These observations are
consistent with rat SCN recordings, where orexin increased
GABAergic neurotransmission in unidentified SCN neurons
(Klisch et al., 2009). In addition, we found that OXA increased
the amplitude of these GABAergic IPSCs, an observation consis-
tent with findings of orexin’s actions in the nucleus ambiguus
(Dergacheva et al., 2011). This indicates that during the day,OXA
Figure8. OXAenhancesNPY’s suppressionof theelectrical activity of SCNclockneurons.A, Representativewhole-cell recording
from a Per1-EGFP neuron showing hyperpolarizing responses to focally applied NPY (40 nM) and bath-applied OXA (80 nM). In the
basal condition, responses of the cell to NPYwere tested twice (Inseta1,a2) to assess reproducibility of its hyperpolarizing effects.
In this particular neuron, 30 s NPY puffs elicited1 min suppression in each trial. OXA was then continuously bath applied (top
graybar). OXA’s effect canbe seen fromb1with a clear hyperpolarizationof theRMPof the cell and inhibition of APs. Before testing
the cell’s response to NPY in the presence of OXA, a positive steady-state current was applied (indicated by the gray square hump)
when OXA’s hyperpolarizing response plateaued. Notice that the cell resumed AP firing when its RMP was returned to the basal
value of43mV. In the presence of OXA, the amplitude andduration of RMP suppression byNPYwere significantly increased (a3)
when compared with NPY alone (compare a3with a1 and a2). c1, After recovery from NPY treatment, the steady-state positive
current was removed. To test whether GABAA receptors are involved, gabazine (20M; black bar on top of gray bar) was then
coappliedwith OXA. Note that blockade of GABAA receptors with gabazine counteracts OXA-hyperpolarizing effects (as in Fig. 4F ),
reverting the cell’s RMP to control value (approximately43mV). In the presence of OXAandgabazine, the hyperpolarizing effect
of NPY (a4 ) was similar to controls (a1, a2).B, Summary of results (amplitude and duration) from Per1-EGFP neurons tested over
the daywith NPY followed by OXANPY (n 15), or NPY followed by OXANPY and OXANPY gabazine (n 5) over the
day. *p 0.05, **p 0.01 denotes significance (one-way ANOVA, Sidak with repeated measures or paired t test). Data are
expressed as mean
 SEM. Number of cells measured is shown in parentheses.
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enhances release of GABA in the SCN, triggering robust GABA-
GABAA receptor-mediated suppression of SCN electrical activity
and [Ca2]i (Fig. 9).
In stark contrast, orexin’s inhibitory actions at night are inde-
pendent of GABAergic signaling, and instead arise through
orexin acting directly to activate background leak K currents
(Figs. 6, 9). These leak channels are important for determining
and maintaining resting membrane potential and excitability in
cells (Mathie, 2007), and expression of their gene transcripts
(Lein et al., 2007) and their physiological activity (Wang et al.,
2012) are reported in the SCN. Here we show that activation of
leak K currents by orexin at night produces robust inhibition of
electrical activity in SCN neurons. To our knowledge, this is the
first description of a direct hyperpolarizing action of orexin in the
brain. Importantly, orexin-mediated inhibition of the SCN
during the night (when orexin neuronal activation and signal-
ing are maximal; Deboer et al., 2004; Zhang et al., 2004) may
therefore serve to reinforce the intrinsic rhythm in SCN elec-
trical activity (Fig. 9). This helps to explain the paradox that
orexin neuronal activity and orexin release are high when SCN
neuronal activity, intracellular calcium levels, and Per gene
expression are low.
Elsewhere in the brain, orexin depolarizes neurons by inhib-
iting K conductances, including leak K currents (Ivanov and
Aston-Jones, 2000; Govindaiah and Cox, 2006), activation of
nonspecific cation channels (Liu et al., 2002; Yang and Ferguson,
2003), or by activating theNa/Ca2 exchanger (Burdakov et al.,
2003). One possible explanation for the apparent novelty of our
findings is that most interrogations of orexin’s actions are per-
formedduring the day on tissue fromnocturnal rodents. Another
study of the nocturnal actions of orexin found that in preoptic
and anterior hypothalamic GnRH neurons, orexin profoundly
suppresses electrical activity in these cells at night (Gaskins and
Moenter, 2012). Hence, clear day–night differences in the re-
sponses and mechanisms of orexin’s actions in the CNS may be
widespread.
The precise contribution of OX1 and OX2 receptors to these
complex actions of orexin in the SCN remains to be fully eluci-
dated. The observation thatOX1 expression is elevated at dusk, in
line with Per2 expression, suggests that themolecular clock could
increase orexin receptor availability at night.Orexin receptors are
promiscuous and can couple both to excitatory and/or inhibitory
G-proteins (Karteris and Randeva, 2003). Since transcripts for
both receptor types are expressed in the SCN, the balance be-
tween inhibitory and excitatory actions of OXA could be dictated
by clock-regulated changes in the G-proteins to which the native
orexin receptors in the SCNare coupled and/or by the differential
expression of OX1 and OX2 (Scammell and Winrow, 2011).
During the day, the circadian rhythms in the SCN clock and in
behavior can be reset by so-called nonphotic/arousal-promoting
stimuli (Mistlberger and Antle, 2011; Hughes and Piggins, 2012).
NPY conveys nonphotic information to the SCN and it is notable
in this study thatOXA enhanced the inhibitory actions ofNPYon
single Per1-EGFP SCN cells as well as augmented its phase-
shifting effects on the SCN molecular clock during the day. In-
triguingly, arousal-promoting stimuli that reset circadian
rhythms in behavior activate lateral hypothalamic orexin neu-
rons (Marston et al., 2008; Webb et al., 2008). Orexin neurons
innervate the IGL (Peyron et al., 1998; McGranaghan and Pig-
gins, 2001;Mintz et al., 2001; Nixon and Smale, 2005), the source
of the NPY innervation of the SCN, and orexin modulates the
activity of IGL cells in vitro (Pekala et al., 2011). Nonphotic reset-
ting is associated with suppression of SCN cellular activity and of
clock gene expression (Maywood et al., 2002) including Per1
(Hamada et al., 2004). Collectively, our results and those of oth-
ers now implicate orexin signaling in the integration of non-
photic information within the SCN.
This suggests that the indirect daytime inhibitory actions of
orexin play amore prominent role in regulating clock phase than
its direct excitatory actions at this time. Further, as orexin is
inhibitory at night and as neither orexin nor other inhibitory
stimuli appear to reset the SCN clock at this time (Brown and
Piggins, 2007), this shows that the orexin’s potential roles in the
SCN vary from day to night. Indeed, the suppressive actions of
orexin at night could act as feedback from aroused behavioral
states to reinforce the molecular clock’s inhibition of SCN neu-
ronal activity (Fig. 9). This suppressive orexinergic signal may be
integral to the Zeitnehmer cues involved with SCN clock entrain-
ment processes (Hughes and Piggins, 2012; Roenneberg et al.,
2013).
Despite the ability of orexin to inhibit daytime electrical activ-
ity within the SCN, this neuropeptide (on its own)was ineffective
at shifting the circadian clockwork. This is an important obser-
vation, in that it indicates that orexin signaling is capable of alle-
viating SCN inhibition of behavioral activity in an acute manner,
Figure 9. Schematic diagram summarizing SCN cellular responses to circadian and arousal-
promoting cues in nocturnal rodents. A, Throughout the subjective day, electrical activity and
inhibitory output from the SCN is high (thick blue line), with orexinergic cells in the lateral
hypothalamus (LH)minimally active, providing nominal/no presynaptic signal (green arrow) to
liberate GABA in the SCN to suppress activity of Per1-EGFP neurons. At this circadian phase, the
inhibitory signal from IGL-NPY cells to the SCN is also at a nadir (thin red line) due to low/no
orexinergic excitatory signal (thin green arrow) to the IGL.B, During the night, electrical activity
and inhibitory output from the SCN is low (thin blue line), with orexinergic cells showing ele-
vated electrical activity, providing strong excitatory input to IGL-NPY cells (thick green arrow)
and large postsynaptic direct inhibitory input to SCN Per1-EGFP cells (thick red line). C, During
daytime, arousal-promoting stimuli activate orexin cells, providing increased orexinergic sig-
naling to the SCN (thick green line). This initially elevates GABA release in the SCN which then
suppresses SCN electrical activity. Increased orexinergic signaling also activates IGL-NPY cells
(thick green arrow),which also provides further suppressive signal to the SCN (thick red line). In
the SCN, orexin facilitates NPY’s inhibitory actions by enhancing GABA signaling. The width of
the arrows (excitatory signal) and T-bars (inhibitory signal) indicates the level of excitation or
inhibition, respectively.D, Circadian variation in SCN (blue line) and orexin (orange line) cellular
activity, and the effects of daytime arousal-promoting stimuli on this activation (broken lines;
Marston et al., 2008; van Oosterhout et al., 2012).
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which does not have lasting impact on circadian rhythmicity
overall. This is especially important in a natural setting where
animals must respond to short-term alterations in the environ-
ment, yet do not want to uncouple overall behavioral rhythmicity
(SCN clock controlled) from prevailing light–dark cycles. This
type of paradigm is well studied, for example, during daytime
restricted feeding of nocturnal rodents (Mistlberger and Antle,
2011). It is noteworthy that mice deficient in orexin signaling
have impaired circadian control of wake and some sleep states
(Mochizuki et al., 2004) and have reduced anticipatory responses
to restricted feeding (Akiyama et al., 2004).
In summary, our findings establish that orexin signaling in the
SCN is mostly inhibitory and relies on intrinsic circadian clock-
controlled membrane properties and neurochemistry of SCN
cells to produce its effects on SCN [Ca2]i and electrical activity.
Here, we also show that orexin acts in the SCN to modulate the
way the master circadian clock responds to other key arousal
inputs. These findings support the view that in vertebrates, orexin
signaling plays pivotal roles in the timing of transitions in brain
and behavioral states (Mochizuki et al., 2004; Elbaz et al., 2012).
Since the neural circadian system is extensive (Sakhi et al., 2013)
and because orexin neurons innervate many components of this
circadian timing circuitry (Peyron et al., 1998), it is important to
understand how orexin signaling integrates with circadian time
cues to influence neuronal activity in these areas. A key implica-
tion is that the mechanisms of orexin’s actions in the SCN switch
from predominantly GABA-mediated presynaptic actions dur-
ing the day to robust direct postsynaptic effects at night.
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